New Research Reports For Apple, MasterCard, JNJ & Others

Friday, September 9, 2016

Today's Research Daily features fresh research reports on 16 major stocks, including Apple (NASDAQ:AAPL), MasterCard (MA), Accenture (ACN) and Johnson & Johnson (NYSE:JNJ). These 16 reports have been hand-picked from amongst the 80 or so research reports issued by our analyst team today. You can see the complete list of today's research reports here >>

Apple’s decision not to release the iPhone 7’s first weekend sales numbers is disappointing, but the Zacks analyst expects the company to benefit from the upgrade cycle even in mature markets. However, concerns about the iPhone maker's long-term growth trajectory remain, particularly with questions about China not going away. Headlines about the $14 billion Irish tax issue aren't helping matters either, though the issue is far from settled at this stage. (You can read the full research report on Apple here>>)

MasterCard shares lagged the broader market earlier in the year, but appear to gained pace following the last quartelry release that showed a rise in the number of processed transactions along with an increase in cross-border volumes. The analyst likes MasterCard’s product-diversification and geographic-expansion initiatives. The company’s multiple acquisitions over the past couple of years are also boosting inorganic growth. (You can read the full research report on MasterCard here>>)

Accenture’s shares have been weak lately, but have done nicely year-to-date. The analyst likes Accenture’s latest product additions in the analytics application space, given the increasing demand for digital solutions. Accenture’s investment in digital and marketing capabilities and its strategy of growing through acquisitions is encouraging. The recent agreement to acquire New Energy Group will further solidify its position as a leading provider of Salesforce’s products and solutions in Europe.(You can read the full research report on Accenture here>>)

Johnson & Johnson shares have bucked the broader healthcare slump this year and are up more than 16% year-to-date. While the company is faced with a number of headwinds like unfavorable currency movements, increased competition from generics, pricing pressures and an uncertain global macroeconomic backdrop, the analyst believes that JNJ's diversified business model, deep product pipeline, lack of cyclicality and financial strength position it for continued momentum going forward. (You can read the full research report on Johnson & Johnson here>>)

You can find all of today's stock research reports here >>>

Free Access: All Zacks Research Reports

Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz Mian publishes a new article, please click here >>